This excerpt taken from the ARRY 10-Q filed Nov 6, 2006.
Note 6: Segment, Geographic and Concentration Information
All operations of the Company are considered to be in one operating segment and, accordingly, no segment disclosures have been presented. The physical location of the Companys property, plant and equipment is within the United States. The following table details revenue from customers by geographic area based on the country in which collaborators are located or the destination where compounds from the Companys inventories are shipped.
Approximately 97% and 94% of the revenue generated from Europe during the three months ended September 30, 2006 and 2005, respectively, is related to the Companys collaboration and licensing agreement with AstraZeneca AB, located in Sweden. For the three months ended September 30, 2006, revenue generated primarily from two Japanese customers represented 14% of total revenue. No other individual international country exceeded 10% of the Companys revenue for the period presented.
During the three months ended September 30, 2006, revenue from four of the Companys customers represented approximately 34%, 27%, 22% and 11% of total revenue, while three of the Companys customers represented approximately 31%, 29% and 18% of total revenue for the comparative period in fiscal 2006.